Priority Review Granted to Novel Pneumococcal Conjugate Vaccine V114
The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.
Pneumonia
Case Series Describes Use of Icosapent Ethyl for COVID-19 Pneumonia
The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube.
Priority Review Granted to 20-Valent Pneumococcal Conjugate Vaccine
The 20vPnC vaccine candidate consists of capsular polysaccharide conjugates for the 13 serotypes included in Prevnar 13, along with 7 additional serotypes that cause invasive pneumococcal disease.
Certain HTN Meds May Cut Deaths From Influenza, Pneumonia
Use of ACE-I/ARB vs nonuse linked to lower mortality for those hospitalized with flu, pneumonia.
Novel Pneumococcal Conjugate Vaccine Immunogenic in Phase 3 Trials
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
Fetroja Approved for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens.
In-Hospital Heart Failure Deaths Down With Routine Vaccinations
Patients with heart failure receiving flu, pneumonia vaccinations have lower in-hospital mortality
MPR Weekly Dose Podcast Episode 45
It’s been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There’s results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting SARS-CVv-2; And researchers have linked vaccination to reduced risks of Alzheimer disease.
Recarbrio Approved for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
The Food and Drug Administration (FDA) has approved Recarbrio™ (imipenem, cilastatin, and relebactam; Merck) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia
Cefiderocol Gets Priority Review for Nosocomial Pneumonia
The FDA has granted Priority Review to cefiderocol (Shionogi) for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible Gram-negative pathogens.
